- Home
- ABEO vs SPXX Comparison
ABEO vs SPXX Comparison
Compare ABEO & SPXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABEO | SPXX |
|---|---|---|
| Founded | 1974 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.0M | 314.9M |
| IPO Year | 1980 | N/A |
Fundamental Metrics
Financial Performance| Metric | ABEO | SPXX |
|---|---|---|
| Price | $5.09 | $18.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $18.20 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 51.3K |
| Earning Date | 03-19-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.55% |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $400,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,589.77 | N/A |
| P/E Ratio | $4.03 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.93 | $13.57 |
| 52 Week High | $7.54 | $16.05 |
Technical Indicators
Market Signals| Indicator | ABEO | SPXX |
|---|---|---|
| Relative Strength Index (RSI) | 46.51 | 52.90 |
| Support Level | $5.00 | $17.85 |
| Resistance Level | $5.41 | $18.06 |
| Average True Range (ATR) | 0.24 | 0.17 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 14.33 | 57.67 |
Price Performance
Historical ComparisonAbout ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
About SPXX Nuveen S&P 500 Dynamic Overwrite Fund
Nuveen S&P 500 Dynamic Overwrite Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total returns with less volatility than the S&P 500 Index by investing in a U.S. equity portfolio that seeks to substantially replicate the price movements of the S&P 500 Index, as well as selling call options on approximately 35%-75% of the notional value of the Fund's equity portfolio in an effort to enhance the Fund's risk-adjusted returns.